Leerink Partnrs Predicts Reduced Earnings for CVS Health

CVS Health Co. (NYSE:CVS) – Investment analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for CVS Health in a research report issued to clients and investors on Wednesday, December 18th. Leerink Partnrs analyst M. Cherny now anticipates that the pharmacy operator will earn $5.21 per share for the year, down from their prior estimate of $5.47. The consensus estimate for CVS Health’s current full-year earnings is $5.32 per share. Leerink Partnrs also issued estimates for CVS Health’s Q1 2025 earnings at $1.30 EPS, Q3 2025 earnings at $1.75 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $6.09 EPS, FY2026 earnings at $7.36 EPS and FY2027 earnings at $8.16 EPS.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. During the same quarter in the prior year, the company earned $2.21 EPS. CVS Health’s revenue was up 6.3% compared to the same quarter last year.

Several other equities analysts have also recently commented on CVS. Wells Fargo & Company raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $60.00 to $66.00 in a research report on Monday, November 18th. Truist Financial reiterated a “buy” rating and issued a $67.00 price objective (down previously from $76.00) on shares of CVS Health in a research note on Wednesday, November 20th. StockNews.com cut shares of CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Piper Sandler dropped their price objective on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research note on Monday, November 25th. Finally, Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $70.50.

CVS Health Trading Up 1.3 %

NYSE CVS opened at $44.36 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The firm’s 50-day moving average is $56.24 and its two-hundred day moving average is $58.24. CVS Health has a 12 month low of $43.60 and a 12 month high of $83.25. The stock has a market capitalization of $55.82 billion, a P/E ratio of 11.26, a PEG ratio of 0.89 and a beta of 0.54.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. &PARTNERS lifted its position in CVS Health by 177.6% during the second quarter. &PARTNERS now owns 14,960 shares of the pharmacy operator’s stock worth $884,000 after acquiring an additional 9,571 shares during the last quarter. JB Capital LLC increased its holdings in CVS Health by 3.1% in the 2nd quarter. JB Capital LLC now owns 11,273 shares of the pharmacy operator’s stock worth $666,000 after purchasing an additional 335 shares in the last quarter. Diversified LLC acquired a new stake in CVS Health during the 2nd quarter worth approximately $212,000. LRI Investments LLC lifted its holdings in shares of CVS Health by 33.0% during the second quarter. LRI Investments LLC now owns 18,092 shares of the pharmacy operator’s stock worth $1,069,000 after purchasing an additional 4,493 shares during the period. Finally, Atlantic Union Bankshares Corp grew its position in shares of CVS Health by 2.9% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 88,774 shares of the pharmacy operator’s stock valued at $5,243,000 after buying an additional 2,509 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.